Latest news
Xenetic Biosciences Q2 royalty revenue rises on Takeda sublicense - TradingViewTradingView · Fri, 07 Aug 2026 12:44:28 GMTXenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss - TradingViewTradingView · Fri, 07 Aug 2026 12:43:12 GMTXenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:35:07 GMT